Mirum Pharmaceuticals Inc (STU:08D)
€ 87.3 +9.16 (+11.72%) Market Cap: 5.33 Bil Enterprise Value: 5.61 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 48/100

Q2 2026 Mirum Pharmaceuticals Inc Earnings Call Transcript

Aug 05, 2026 / 08:30PM GMT
Release Date Price: €90.8 (+0.27%)
Operator

Good afternoon, and welcome to Mirum Pharmaceuticals' second quarter 2026 earnings conference call. My name is Alexandra, and I will be your operator today. (Operator Instructions)

I would now like to hand the conference over to Andrew McKibben, SVP of Strategic Finance and Investor Relations. Please go ahead.

Andrew McKibben
Mirum Pharmaceuticals, Inc. - Senior Vice President - Strategic Finance & Investor Relations

Thank you, Alexandra, and good afternoon, everyone. I'd like to welcome you to Mirum Pharmaceuticals' second quarter 2026 conference call. I'm joined today by our Chief Executive Officer, Chris Peetz, our President and Chief Operating Officer, Peter Radovich, and Eric Bjerkholt, our Chief Financial Officer. Lara Longpre, our Chief Development Officer, will be joining us for the Q&A portion of the call. Joanne Quan, our Chief Medical Officer, could not be with us today due to a family matter. Earlier today, Mirum issued a press release announcing the company's results for the second quarter of 2026. Copies of the press release and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot